BIO-TECHNE Corp 4

Insider Amy E. Herr, through her significant other, received a fully vested award of 1,381 Bio‑Techne Corp common shares via restricted stock units on 2026-08-17.

On August 17, 2026, Bio‑Techne Corp director (or similar insider) Amy E. Herr, reporting indirectly through her significant other, received an award of 1,381 restricted stock units (RSUs) that fully vested on the grant date, increasing indirect beneficial ownership of common stock. The filing also discloses a wide set of existing option grants with exercise prices ranging from $53.60 to $120.46 and expirations from 2027 to 2035, as well as previously granted RSUs with multi‑year vesting schedules; however, these options and prior RSUs were not newly granted or exercised in this Form 4, but are provided as context for outstanding derivative securities and future equity vesting. Following the fully vested RSU award, Herr’s indirect holdings through her significant other rose to 1,381 additional shares of common stock, while she and her significant other also continue to hold various stock options and RSUs that may convert into additional common shares upon future vesting or exercise.

Filing Facts

CIK

842023

Ticker

TECH

Form

4

Source Type

fda

Accession

0000914190-26-000131

Alert Tier

5